Last reviewed 2026-04-19 · How we verify

Cohort 1 of Y101D

Wuhan YZY Biopharma Co., Ltd. · Phase 1 active Small molecule

Cohort 1 of Y101D is a Small molecule drug developed by Wuhan YZY Biopharma Co., Ltd.. It is currently in Phase 1 development.

At a glance

Generic name	Cohort 1 of Y101D
Sponsor	Wuhan YZY Biopharma Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cohort 1 of Y101D CI brief — competitive landscape report
Cohort 1 of Y101D updates RSS · CI watch RSS
Wuhan YZY Biopharma Co., Ltd. portfolio CI

Frequently asked questions about Cohort 1 of Y101D

What is Cohort 1 of Y101D?

Cohort 1 of Y101D is a Small molecule drug developed by Wuhan YZY Biopharma Co., Ltd..

Who makes Cohort 1 of Y101D?

Cohort 1 of Y101D is developed by Wuhan YZY Biopharma Co., Ltd. (see full Wuhan YZY Biopharma Co., Ltd. pipeline at /company/wuhan-yzy-biopharma-co-ltd).

What development phase is Cohort 1 of Y101D in?

Cohort 1 of Y101D is in Phase 1.

Manufacturer: Wuhan YZY Biopharma Co., Ltd. — full pipeline